<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human B cells detect CpG motifs within microbial DNA via TLR9 </plain></SENT>
<SENT sid="1" pm="."><plain>Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is only limited information on the CpG oligodeoxynucleotide sensitivity of primary malignant B cells of different non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> entities </plain></SENT>
<SENT sid="3" pm="."><plain>Here we found that most B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> except <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation </plain></SENT>
<SENT sid="4" pm="."><plain>In an in vitro analysis of 41 individual patient-derived <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> samples, B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (B-CLL) and marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed the strongest activation upon stimulation with CpG oligodeoxynucleotides </plain></SENT>
<SENT sid="5" pm="."><plain>Small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed an intermediate response </plain></SENT>
<SENT sid="6" pm="."><plain>Consistent with CpG oligodeoxynucleotides sensitivity, TLR9 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was present in B-CLL but absent in <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Although CpG oligodeoxynucleotides induced proliferation in <z:hpo ids='HP_0000001'>all</z:hpo> CpG oligodeoxynucleotide-sensitive types of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, proliferation was weaker than in <z:mpath ids='MPATH_458'>normal</z:mpath> B cells and at least for B-CLL was followed by <z:mp ids='MP_0006042'>increased apoptosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> show significant differences in their responsiveness to CpG oligodeoxynucleotides </plain></SENT>
<SENT sid="9" pm="."><plain>Focusing clinical studies on patients with highly CpG oligodeoxynucleotide-sensitive B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> may improve the clinical outcome of such trials </plain></SENT>
</text></document>